SAHPRA + research peptides — South Africa's pharmaceutical-import framework

SAHPRA was established by the National Department of Health and operates under the Medicines and Related Substances Act 101 of 1965 (as amended through SAHPRA legislation in 2017). SAHPRA registers and regulates medicines, medical devices, and complementary medicines in South Africa. The Act schedules substances into eight schedules — Schedule 0 (general sale) through Schedule 7 (manufacture/import only by registered persons). Most research peptides without SAHPRA registration are unregistered medicines under Section 14 of the Act.

For research-use substances, SAHPRA operates a Section 21 exemption pathway. Section 21 allows registered medical practitioners and research institutions to access unregistered medicines for individual patient use or documented research. The pathway requires: (a) practitioner application or research-institution application, (b) IRB / ethics committee approval for research, (c) ongoing reporting. SA universities (Wits, UCT, Stellenbosch, Pretoria) routinely use Section 21 for institutional peptide research. The pathway is well-established and predictable.

For research-use-only substances sold as research chemicals — the peptide vendor model — the SAHPRA posture is more permissive than the strict-import frameworks of TGA / SFDA / PMDA. Substances clearly labelled "for laboratory research, not for human use" sit outside the registered-medicines framework when sold to research institutions. The grey zone is when these same substances are sold to individual buyers; SAHPRA enforcement against individual buyers has been minimal, focused instead on vendors who market peptides as supplements or with health claims.

Two SA-domestic vendors — Reschem and Ultra Labs SA — operate openly in South Africa. Reschem is the larger of the two, with HPLC + LC-MS COAs, ZAR pricing, and SA-domestic shipping (1–3 days nationwide). Ultra Labs SA specializes in collagen and anti-aging peptides (GHK-Cu, etc) and offers a lower free-shipping threshold. Both maintain research-use-only labelling. Neither has attracted SAHPRA warning letters. The SA-domestic vendor pair is the cleanest path for SA-resident researchers.

For other African countries (Nigeria, Kenya, Egypt, etc.), the SA-domestic option doesn't apply — Reschem ships internationally but with regional African shipping less developed than its SA-domestic logistics. Cross-border shipments rely on courier partnerships (DHL is most common) and face country-specific customs frameworks (covered in the country-specific articles below).

For SA institutional researchers, the Section 21 pathway provides a legitimate route for non-registered peptide imports. The pathway is well-established and most SA university research labs use it. Researchers in academic positions should use institutional procurement before considering personal-purchase routes.

On WADA / sport-doping side, SAIDS (South African Institute for Drug-Free Sport) is WADA-aligned and tests SA athletes in the standard WADA framework. Research peptides prohibited under S0; BPC-157 named explicitly since 2022. Cricket South Africa, SAFA (soccer), and SARU (rugby) have all sanctioned peptide-positive players. For tested SA athletes, WADA framework rules apply.

More from this region.

Other articles covering this region's vendors, regulatory framework, and research peptides.